GlassScriptPhysician profile
Cindy C Pratt
NPI 1114990595
$5,227.90
in general payments reported to CMS, 2019-2025
32 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,343 · 2022: $1,263 · 2023: $1,748 · 2024: $747 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,621.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $499.48 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $345.97 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $328.54 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $285.04 | 2021-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $269.81 | 2022-2024 | |
| Abbott Laboratories | $258.20 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $253.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.47 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $214.60 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $179.64 | 2022-2025 | Rexulti |
| Pfizer INC. | $175.91 | 2021-2025 | |
| Dexcom, INC. | $148.95 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $146.02 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $142.14 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.89 | 2021 | |
| Glaxosmithkline, LLC. | $87.60 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Sumitomo Pharma America, INC. | $81.00 | 2023-2024 | Gemtesa |
| Dynavax Technologies Corporation | $64.55 | 2023-2024 | Heplisav-B |
| Seqirus USA INC | $58.97 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.55 | 2021-2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $40.00 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $39.56 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $38.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.85 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $17.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.52 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $14.39 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.27 | 2021 | |
| Clarus Therapeutics INC. | $9.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.